EVOLVE-IBERIA: Real-world evidence on vedolizumab and anti-tumour necrosis factor-α as first- and second-line biologic treatment in Crohn's disease. // Gastroenterología y Hepatología. – URL: https://www.sciencedirect.com/science/article/pii/S0210570526009611?dgcid=rss_sd_all
EVOLVE-IBERIA: Real-world evidence on vedolizumab and anti-tumour necrosis factor-α as first- and second-line biologic treatment in Crohn's disease. Gastroenterología y Hepatología. https://www.sciencedirect.com/science/article/pii/S0210570526009611?dgcid=rss_sd_all
“EVOLVE-IBERIA: Real-world evidence on vedolizumab and anti-tumour necrosis factor-α as first- and second-line biologic treatment in Crohn's disease.” Gastroenterología y Hepatología.
@article{article46986,
title = {EVOLVE-IBERIA: Real-world evidence on vedolizumab and anti-tumour necrosis factor-α as first- and second-line biologic treatment in Crohn's disease},
journal = {Gastroenterología y Hepatología},
url = {https://www.sciencedirect.com/science/article/pii/S0210570526009611?dgcid=rss_sd_all}
}